DOTAP/DC-CHOL Cationic LiposomesProduct code:F50101VLipid composition: DOTAP/DC-Cholesterol (50:50 mol/mol)Mean particle size:50-80 nm (by DSL)Lipid concentration: 40 mM (24.7 mg/mL)Volume:2.0mLBulk solution:D5W (dextrose in milli-Q water)Shelf-life:6 monthsguaranteed for sterility for unopened vials stored at 2-8 degree C (guaranteedstarting from the date of delivery, replacement only)DOTAP:1,2-dioleoyl-3-trimethylammonium-propane (chloride salt)DC-CHOL:DC-Cholesterol∙HCl, 3b-[N-(N",N"-dimethylaminoethane)-caramoyl]chelesterol hydrochlorideAttachment of class B CpG ODN ontoDOTAP/DC-cholliposomein nasalvaccineformulations augments antigen-specificimmuneresponses in mice.Tada R, Muto S, Iwata T, Hidaka A, Kiyono H, Kunisawa J, Aramaki Y.BMC Res Notes. 2017 Jan 26;10(1):68. doi: 10.1186/s13104-017-2380-8.PMID:28126014Nasalvaccinationwith pneumococcal surface protein A in combination with cationicliposomesconsisting ofDOTAPandDC-cholconfers antigen-mediated protectiveimmunityagainst Streptococcus pneumoniae infections in mice.Tada R, Suzuki H, Takahashi S, Negishi Y, Kiyono H, Kunisawa J, Aramaki Y.Int Immunopharmacol. 2018 Aug;61:385-393.Comparison of the depot effect and immunogenicity ofliposomesbased on dimethyldioctadecylammonium (DDA), 3β-[N-(N",N"-Dimethylaminoethane)carbomyl] cholesterol (DC-Chol), and 1,2-Dioleoyl-3-trimethylammonium propane (DOTAP): prolongedliposomeretention mediates stronger Th1 responses.Henriksen-Lacey M, Christensen D, Bramwell VW, Lindenstrøm T, Agger EM, Andersen P, Perrie Y.Mol Pharm. 2011 Feb 7;8(1):153-61.Cationic DDA/TDBliposomeas a mucosalvaccineadjuvant for uptake by dendritic cells in vitro induces potent humouralimmunity.Qu W, Li N, Yu R, Zuo W, Fu T, Fei W, Hou Y, Liu Y, Yang J.Artif Cells Nanomed Biotechnol. 2018;46(sup1):852-860.IntranasalImmunizationwithDOTAPCationicLiposomesCombined with DC-Cholesterol Induces Potent Antigen-Specific Mucosal and SystemicImmuneResponses in Mice.Tada R, Hidaka A, Iwase N, Takahashi S, Yamakita Y, Iwata T, Muto S, Sato E, Takayama N, Honjo E, Kiyono H, Kunisawa J, Aramaki Y.PLoS One. 2015 Oct 6;10(10):e0139785. doi: 10.1371/journal.pone.0139785. eCollection 2015.PMID:26440657Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.Hadinoto K, Sundaresan A, Cheow WS.Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):427-43.Intranasal administration of cationicliposomesenhanced granulocyte-macrophage colony-stimulating factor expression and this expression is dispensable for mucosal adjuvant activity.Tada R, Hidaka A, Kiyono H, Kunisawa J, Aramaki Y.BMC Res Notes. 2018 Jul 13;11(1):472.Predicting the influence ofliposomallipid composition onliposomesize, zeta potential andliposome-induced dendritic cell maturation using a design of experiments approach.Soema PC, Willems GJ, Jiskoot W, Amorij JP, Kersten GF.Eur J Pharm Biopharm. 2015 Aug;94:427-35.Liposome-mediated DNAimmunisationvia the subcutaneous route.Perrie Y, McNeil S, Vangala A.J Drug Target. 2003;11(8-10):555-63.Lipoplexes formulation and optimisation: in vitro transfection studies reveal no correlation with in vivovaccinationstudies.McNeil SE, Vangala A, Bramwell VW, Hanson PJ, Perrie Y.Curr Drug Deliv. 2010 Apr;7(2):175-87.A new intranasal influenzavaccinebased on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.Joseph A, Itskovitz-Cooper N, Samira S, Flasterstein O, Eliyahu H, Simberg D, Goldwaser I, Barenholz Y, Kedar E.Vaccine. 2006 May 1;24(18):3990-4006.Cationicliposomespromote antigen cross-presentation in dendritic cells by alkalizing the lysosomal pH and limiting the degradation of antigens.Gao J, Ochyl LJ, Yang E, Moon JJ.Int J Nanomedicine. 2017 Feb 14;12:1251-1264.Transcutaneousimmunizationby lipoplex-patch based DNAvaccinesis effectivevaccinationagainst Japanese encephalitis virus infection.Cheng JY, Huang HN, Tseng WC, Li TL, Chan YL, Cheng KC, Wu CJ.J Control Release. 2009 May 5;135(3):242-9.

FormuMax科学公司位于加利福尼亚州北部硅谷的中心地带，是一家专业的药品配送公司，致力于满足医药/生物技术、化妆品和保健工业的配方开发外包的日益增长的需求。经营理念是成为**的伙伴，作为药物交付的***，特别是在制定具有挑战性的化合物脂质体和其他新的纳米技术。FormuMax拥有一支技术团队，在药物递送领域拥有***的专业知识，特别关注脂质体和其他基于脂质的技术。它们目前提供基础研究，配方可行性，定制配方准备，配方表征和分析科学的合同服务。FormuMax是**家提供大量预成型脂质体试剂的在线商店。已经成功地为来自世界各地的大学实验室、研究中心和各种行业的客户提供了服务和/或产品。